Twist Bioscience Corporation (NASDAQ: TWST) raised its fiscal 2026 full-year sales guidance to $456 million-$457 million, up from the previous range of $442 million-$447 million, following a third-quarter revenue beat. The life sciences company reported Q3FY26 revenue of $118.376 million, surpassing the consensus estimate of $114.49 million and management’s prior guidance of $114 million-$115 million. Despite the top-line strength, the company reported an adjusted loss of 56 cents per share, missing the consensus loss estimate of 50 cents. The guidance increase signals management’s confidence in demand momentum entering the final quarter of the fiscal year.

The stock rose 8.55% to $99.30 on Monday as investors reacted to the improved outlook and expanding opportunities in AI-enabled drug discovery. CEO Emily Leproust stated that the company remains on track to achieve adjusted EBITDA breakeven in the fourth quarter, a milestone she described as the foundation for profitable growth in fiscal 2027. Twist Bio also forecast Q4FY26 sales of $123 million-$124 million, beating the consensus estimate of $117.55 million.

Segment Performance and Operational Metrics

Revenue growth was driven by both core business segments. DNA Synthesis and Protein Solutions (DSPS) revenue grew 39% year-over-year to $56.6 million. NGS Applications revenue increased 12% to $61.8 million. The company shipped products to approximately 2,650 customers in Q3FY26, an increase from 2,480 customers in the same period last year. Additionally, Twist Bio manufactured approximately 369,000 genes, compared to roughly 237,000 genes a year ago, indicating consecutive quarter-over-quarter growth in gene manufacturing for data characterization.

AI Drug Discovery Pipeline Expansion

A key driver of the optimistic outlook is the expanding funnel for AI-enabled drug discovery. Leproust noted that the company has the potential to post triple-digit percentage order growth in this segment for fiscal 2027 compared to fiscal 2026. This expansion aligns with the broader industry trend toward integrating generative biology with traditional drug development workflows. The company expects its gross margin for fiscal 2026 to exceed 52%, reflecting operational efficiency gains despite the current period’s losses.

What the Numbers Show

The divergence between the revenue beat and the EPS miss highlights the transitional nature of Twist Bioscience’s financial profile. While top-line growth is accelerating—evidenced by the 23% year-over-year revenue increase and strong customer acquisition—the path to profitability remains constrained by cost structures. However, the raise in full-year guidance and the specific target of EBITDA breakeven in Q4 suggest that operational leverage is beginning to take effect. The significant growth in DSPS revenue (39%) outpacing NGS Applications (12%) indicates a shifting demand mix toward higher-value synthesis services, which may support margin expansion in subsequent quarters.

Twist Bioscience (NASDAQ: TWST) raised its full-year FY2026 sales guidance to a range of $456.000 million to $457.000 million, surpassing the consensus analyst estimate of $446.103 million. The company previously projected revenues between $442.000 million and $447.000 million for the fiscal year. This upward revision signals stronger-than-anticipated demand and improved commercial execution across its synthetic biology portfolio.

The update reflects a significant positive deviation from market expectations, with even the lower bound of the new guidance exceeding the consensus view by nearly $10 million. This adjustment underscores confidence in the company’s ability to capture market share and accelerate revenue generation in the coming quarters.

Updated Financial Guidance

The revision adds approximately $14 million to the lower end of the revenue outlook and $10 million to the upper end compared to prior projections. Investors will monitor how this top-line strength translates into profitability metrics in subsequent earnings reports.

What the Numbers Show

The primary analytical takeaway is the clear outperformance relative to both internal forecasts and external estimates. The gap between the new low-end guidance ($456.000 million) and the analyst estimate ($446.103 million) represents a material beat of roughly $9.9 million. This divergence suggests that Twist Bioscience’s commercial strategy is gaining traction faster than anticipated, potentially driven by robust order intake or accelerated delivery timelines in key segments. For shareholders, this positive surprise reduces downside risk and establishes a higher baseline for future performance comparisons.